Literature DB >> 1184736

Partial purification and characterization of contact activation cofactor.

S Schiffman, P Lee.   

Abstract

The contact phase of intrinsic clotting involves Factor XI, Factor XII, Fletcher factor, and a fourth activity that we call contact activation cofactor (CAC). All four of these activities are reduced or absent in Dicalite-adsorbed plasma. A modified activated partial thromboplastin time assay for CAC has been defined by using a substrate of Dicalite-adsorbed plasma combined with partially purified sources of Factors XI and XII, and Fletcher factor. The following properties of CAC in plasma have been determined by using the assay: it is stable up to 60 min at 56 degrees C; gradually loses activity at 80 degrees C; is stable between pH 6 and 9; is precipitated by ammonium sulfate between 40% and 50% saturation; is slightly adsorbed by A1(OH)3; and is eluted from DEAE-cellulose after the major protein peaks. A purification procedure has been devised that separates CAC from other known clotting factors. Isolated CAC was less stable than CAC in plasma, but in the presence of dilute human serum albumin it retained full activity for 80 min at 56 degrees C. On gel filtration CAC had an apparent mol wt of 220,000 daltons. These properties are consistent with those described for Fitzgerald factor, which further supports the conclusion that CAC and Fitzgerald factor represent the same activity. Isolated CAC promoted the generation of activated Factor XI (XIa) in a mixture containing purified Factor XI, Factor XII, and kaolin. The amount of Factor XIa generated was proportional to the amount of added CAC. No time-consuming reaction between Factor XI or Factor XII and CAC could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184736      PMCID: PMC301969          DOI: 10.1172/JCI108182

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Identity of contact activation cofactor and Fitzgerald factor.

Authors:  S Schiffman; P Lee; R Waldmann
Journal:  Thromb Res       Date:  1975-05       Impact factor: 3.944

2.  Origin of the high molecular weight activator of prekallikrein.

Authors:  A Bagdasarian; B Lahiri; R W Colman
Journal:  J Biol Chem       Date:  1973-11-25       Impact factor: 5.157

3.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

4.  Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors.

Authors:  D Ogston; C M Ogston; O D Ratnoff; C D Forbes
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

5.  Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma.

Authors:  H Saito; O D Ratnoff; V H Donaldson
Journal:  Circ Res       Date:  1974-05       Impact factor: 17.367

Review 6.  Estimation of molecular size and molecular weights of biological compounds by gel filtration.

Authors:  P Andrews
Journal:  Methods Biochem Anal       Date:  1970

Review 7.  The biology and pathology of the initial stages of blood coagulation.

Authors:  O D Ratnoff
Journal:  Prog Hematol       Date:  1966

8.  Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

9.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  15 in total

1.  Purification of high molecular weight kininogen and the role of this agent in blood coagulation.

Authors:  H Saito
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.

Authors:  V H Donaldson; J Kleniewski; H Saito; J K Sayed
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

6.  Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.

Authors:  O D Ratnoff; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Surface activation of factor XII (Hageman factor)--critical role of high molecular weight kininogen and another potentiator).

Authors:  J Y Chan; C E Burrowes; H Z Movat
Journal:  Agents Actions       Date:  1978-01

8.  The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.

Authors:  S D Revak; C G Cochrane; J H Griffin
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

9.  Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate.

Authors:  C F Scott; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Authors:  R C Wiggins; B N Bouma; C G Cochrane; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.